Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Glioblastoma 2Brain Neoplasms 2

Interventions

Temozolomide 69Bevacizumab 40Radiotherapy 22Magnetic Resonance Spectroscopy 20Irinotecan 17Specimen Handling 10Carboplatin 10Carmustine 9X-Rays 7Radiation 7olaparib 6Surgical Procedures, Operative 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Nivolumab 6Everolimus 6Cyclophosphamide 6Biopsy 6trametinib 5Thalidomide 5Cisplatin 5pembrolizumab 4palbociclib 4fluorodopa F 18 4erdafitinib 4dabrafenib 4Lomustine 4Etoposide 4Drug Therapy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Glioma × Dianhydrogalactitol × Clear all
NCT03050736 2025-09-04

Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression

Kintara Therapeutics, Inc.

Phase 2 Completed
29 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT02717962 2025-08-29

Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

Kintara Therapeutics, Inc.

Phase 2 Completed
118 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡